Sign in

    Matthew Venizio • Alliance Global Partners

    Matthew Venezia is a Stock Analyst at Alliance Global Partners specializing in healthcare and biotechnology sectors, with coverage including companies such as Pluri Inc. and Cibus. His track record features a success rate of 33.33% and an average return of -42.06%, ranking #4,677 out of 4,847 analysts on Stock Analysis, and he has covered a total of 4 stocks. Venezia began his analyst role at Alliance Global Partners in recent years, with limited publicly available details on previous firms. He is recognized on financial research platforms like TipRanks, but specific information regarding FINRA registration or securities licenses is not disclosed.

    Matthew Venizio's questions to Cibus Inc (CBUS) leadership

    Matthew Venizio's questions to Cibus Inc (CBUS) leadership • Q2 2025

    Question

    Matthew Venizio of Alliance Global Partners inquired about a recent germplasm transfer for the Rice HT3 trait, asking if it was for a new or existing customer's field trials. He also sought clarification on the timing of initial revenues, specifically regarding the biofragrance program's shift into 2026 and whether those revenues would be royalty-based.

    Answer

    Co-Founder & CSO Greg Gochel confirmed the transfer was to a new U.S. customer for their own field trials. Co-Founder & Interim CEO Peter Beethen clarified that while nominal revenues from biofragrance scale-up material are expected in late 2025, the main commercial ramp and royalty-based revenue model will begin in 2026.

    Ask Fintool Equity Research AI